Berenberg sees 21% upside in Lilly ahead of EASD data
The note cites upcoming European presentations on Foundayo and retatrutide as catalysts for Eli Lilly shares.
TR
By Tom Reyes · Markets Editor
Sep 15 09:52 ETSource: finance.yahoo.com
The wire
- 01Berenberg flagged roughly 21% potential upside in Eli Lilly stock.
- 02Analyst optimism ties directly to fresh Foundayo and retatrutide datasets due in Europe.
- 03Whether the data support the thesis will not be known until presentations occur.
From the source
Read at news.google.comEli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe – Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock